





CURRENTLY ACTIVE CLINICAL TRIALS

OCULAR SURFACE AREA

SPONSOR	TRIAL NAME	PROTOCOL CODE	
 mc2 biotek	PAD-Ciclo	MC-03-C1	A phase II, multicenter, randomized, double-masked, 4 parallel arms, controlled 6-month trial designed to evaluate the safety and efficacy of PAD Coclisporin (CsA 0.06% and 0.03%) ophthalmic dispersion administered once daily in combination with lubricant therapy and a 3-month post treatment safety follow-up in moderate to severe dry eye patients.
 LABORATORIOS Thea	CACICOL	LT40-20-302	Performance and safety assessment of T4020 combined with standard post-operative therapy versus standard post-operative therapy in managing corneal epithelial defect following epi-off accelerated corneal crosslinking.
 AVX PHARMA	AVIZOREX	AVX012-CT-001	A phase I/II double-blind, placebo-controlled study assessing the safety and efficacy of AVX-012 ophthalmic solution in subjects with mild to moderate dry eye syndrome.
 sylentis	HELIX	S33E1601 / SYL1001_IV: Helix/ Sylentis	A double-masked study of SYL1001 in patients with moderate to severe dry eye disease (DED).

